AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
2min chapter
33. B-Cell Depleting Therapies and COVID-19
ACR on Air
The Benefits of Ever Shield for Immunosuppressed Patients
The length between the last dose of retuximab sort of plays a big role in, you know, how likely you are to respond to vaccines. Maybe getting a added doses, especially if you're further out from the initial dose might help. Anything else that patients on B cell depleting therapies can do to try to mitigate the risk of COVID infection? Yeah, so this goes into now probably the biggest saving grace for our immunosuppressed patients, and that's the ever Shield. Ever shield is a combination of two monoclonal antibodies that were actually isolated from two patients that had convalesced from COVID-19.
00:00
Transcript
Episode notes
Get the Snipd
podcast app
Unlock the knowledge in podcasts with the podcast player of the future.
AI-powered
Discover
highlights
Listen to the best highlights from the podcasts you love and dive into the full episode
Save any
moment
Hear something you like? Tap your headphones to save it with AI-generated key takeaways
Share
& Export
Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more
AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
Discover
highlights
Listen to the best highlights from the podcasts you love and dive into the full episode